MarginsXMarginsX
Home › Markets › Health Care › ELOX

Eloxx Pharmaceuticals Inc. (ELOX)

ELOX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.75
-3.04% on the day
Market cap
$51.5M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$6.0M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/0001193125-26-108687-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerELOX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001035354
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$6.0M
Operating income-$6.4M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$4.8M
Total assets$5.3M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
68.9 months
$62.0M cash at June 30, 2026
Share count, 1 year
No year-earlier count
+46.6% over 3 years
Going-concern doubt
No
10-Q filed August 11, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-11
Cash and burn$62.0M cash; operating cash flow -$2.7M a quarter.Report 2026-06-30
Shares outstanding4,036,459 (2026-08-07); 2,752,774 three years earlier.Cover page 2026-08-07
Reverse splits, 3 years1; latest on 2026-06-01Source 2026-06-01
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, Tewksbury, Massachusetts, United StatesPCAOB Form AP 2026-07-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
Not filed-$4.5M-$4.8M$62.0M$0Needs four quarters10-Q 2026-08-11
Q3 2026
2026-03-31
Not filed-$3.8M-$5.5M$6.4M$0Needs four quarters10-Q 2026-08-11
Q4 2025
2025-06-30
Not filed-$1.9M-$1.8M$572KNo debt tagsNeeds four quarters10-Q 2026-08-11
Q3 2025
2025-03-31
Not filed-$1.7M$1.2M$450KNo debt tagsNeeds four quarters10-Q 2026-08-11
Q2 2024
2023-12-31
Not filed-$2.9M-$2.0M$1.1M$3.8M$010-K 2026-03-17
Q1 2024
2023-09-30
Not filed-$3.6M-$3.5M$4.8M$4.6MNeeds four quarters10-Q 2023-11-13
Q4 2023
2023-06-30
Not filed-$4.3M-$2.1M$4.3M$4.8MNeeds four quarters10-Q 2023-11-13
Q3 2023
2023-03-31
Not filed-$6.2M-$6.8M$4.9M$4.7MNeeds four quarters10-Q 2023-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-16
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxy
FORM DEFA14A
DEFA14A2023-04-28

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.7%
1 month+3.5%
3 months-31.0%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-37.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
GRMLGreenland Mines Ltd.$3.50-3.05%$51.9M
INKTMiNK Therapeutics Inc.$9.35+0.11%$48.0M
PMCBPharmaCyte Biotech Inc.$5.57-16.62%$59.8M
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M
CSBRChampions Oncology Inc.$4.68-0.53%$65.1M
ATRAAtara Biotherapeutics Inc.$6.40-16.88%$65.2M
CRDFCardiff Oncology Inc.$0.8477+16.75%$65.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier